► Subscribe to the Financial Times on YouTube: http://bit.ly/FTimeSubs
A decision by the UK’s National Health Service not to stock a new cancer drug being sold by AstraZeneca has seen the British pharmaceuticals company accuse the country of stymieing scientific innovation. The FT's Andrew Ward explains the predicament.
► FT Business: http://bit.ly/1KUK08s
► FT Markets: http://bit.ly/1J5HNd3
► NHS Struggles to Boost Productivity: http://bit.ly/1er08o1
